APA (7th ed.) Citation

Ramgi, P., Siribie, M., Rakotozandrindrainy, N., Bule, O., Shrivastava, H., Chambule, L., . . . Marks, F. (2025). Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique. Clinical infectious diseases, 80, . https://doi.org/10.1093/cid/ciaf130

Chicago Style (17th ed.) Citation

Ramgi, Patrícia, et al. "Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique." Clinical Infectious Diseases 80 (2025). https://doi.org/10.1093/cid/ciaf130.

MLA (9th ed.) Citation

Ramgi, Patrícia, et al. "Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique." Clinical Infectious Diseases, vol. 80, 2025, https://doi.org/10.1093/cid/ciaf130.